MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel

Core Insights - MiMedx Group, Inc. has entered into an exclusive agreement with Regen Lab USA LLC to distribute the RegenKit-Wound Gel in the United States, enhancing its wound care product offerings [1][2]. Company Developments - The RegenKit-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that effectively concentrates essential growth factors and nutrients while removing iron-laden red blood cells [2]. - This product is backed by multiple studies demonstrating its effectiveness in treating chronic wounds and is covered nationally by CMS and LCD for diabetic chronic wounds under HCPCS code G0465 [2]. Strategic Positioning - The addition of RegenKit is expected to complement MiMedx's existing wound care portfolio, providing a broader range of proven solutions for patients and healthcare professionals [3]. - The company anticipates that this agreement, along with the clarity on Local Coverage Determination (LCD) implementation effective January 1, 2026, will strengthen its competitive position as it enters the new year [3]. About Regen Lab USA LLC - Regen Lab USA LLC is a leader in autologous regenerative medicine, specializing in high-quality medical devices for cell therapies and the preparation of autologous PRP from patients' own blood [4]. About MiMedx - MiMedx is a pioneer in wound care, focusing on innovative solutions to help manage chronic and hard-to-heal wounds, with a vision to be the leading global provider of healing solutions [5].